Starpharma Holdings Limited
OTC: SPHRY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cheryl Maley
- Employees
- 40
- Headquarters
- Abbotsford, Australia
- IPO year
- 2007
- Market cap
- $200.2M
- Website
- https://starpharma.com
Loading SPHRY…
Loading profile data…Frequently asked questions about SPHRY
What does Starpharma Holdings Limited (SPHRY) do?
Starpharma Holdings Limited is an Australian biopharmaceutical company dedicated to advancing and marketing its proprietary dendrimer technology across global pharmaceutical, life-science, and other sectors. Among its current offerings are VivaGel, a non-antibiotic treatment designed for the management and prevention of bacterial vaginosis, alon...
Where does SPHRY trade?
Starpharma Holdings Limited (SPHRY) trades on the Other OTC.
What sector is SPHRY in?
Starpharma Holdings Limited (SPHRY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Starpharma Holdings Limited?
Cheryl Maley is the chief executive officer of Starpharma Holdings Limited (SPHRY).
Where is Starpharma Holdings Limited headquartered?
Starpharma Holdings Limited is headquartered in Australia.
Does SPHRY pay a dividend?
Starpharma Holdings Limited (SPHRY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SPHRY go public?
Starpharma Holdings Limited (SPHRY) completed its initial public offering in 2007.
Is SPHRY an ADR?
Yes — SPHRY is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Starpharma Holdings Limited reporting and dividends follow the underlying issuer.